while the 36-month beta value is 0.62.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Outlook Therapeutics Inc. (OTLK) is $6.68, which is $5.33 above the current market price. The public float for OTLK is 109.67M, and currently, short sellers hold a 14.93% ratio of that floaft. The average trading volume of OTLK on May 26, 2023 was 683.55K shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
OTLK) stock’s latest price update
The stock price of Outlook Therapeutics Inc. (NASDAQ: OTLK) has dropped by -9.40 compared to previous close of 1.49. Despite this, the company has seen a gain of 10.66% in its stock price over the last five trading days.
OTLK’s Market Performance
OTLK’s stock has risen by 10.66% in the past week, with a monthly rise of 25.00% and a quarterly rise of 18.42%. The volatility ratio for the week is 13.84% while the volatility levels for the last 30 days are 7.50% for Outlook Therapeutics Inc. The simple moving average for the past 20 days is 10.97% for OTLK’s stock, with a 20.00% simple moving average for the past 200 days.
OTLK Trading at 20.17% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.59% of loss for the given period.
Volatility was left at 7.50%, however, over the last 30 days, the volatility rate increased by 13.84%, as shares surge +27.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.66% upper at present.
During the last 5 trading sessions, OTLK rose by +10.66%, which changed the moving average for the period of 200-days by +13.45% in comparison to the 20-day moving average, which settled at $1.2310. In addition, Outlook Therapeutics Inc. saw 25.00% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at OTLK starting from Dagnon Terry, who sale 520,000 shares at the price of $1.14 back on Apr 20. After this action, Dagnon Terry now owns 653,058 shares of Outlook Therapeutics Inc., valued at $590,200 using the latest closing price.
Evanson Jeff, the Chief Commercial Officer of Outlook Therapeutics Inc., sale 267,000 shares at $1.11 during a trade that took place back on Jan 20, which means that Evanson Jeff is holding 745,975 shares at $296,370 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at -348.41, while invested capital returns managed to touch -544.15. Equity return is now at value -415.50, with -124.50 for asset returns.
Based on Outlook Therapeutics Inc. (OTLK), the company’s capital structure generated 125.43 points at debt to equity in total, while total debt to capital is 55.64. Total debt to assets is 38.41, with long-term debt to equity ratio resting at 0.05. Finally, the long-term debt to capital ratio is 0.02.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.39.
In a nutshell, Outlook Therapeutics Inc. (OTLK) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.